DRUG · Unmapped registry intervention
ADT
Find medicine records ·
Find other trials using this name
Clinical trial
Brexpiprazole as Adjunctive Therapy With Major Depressive Disorder and an Inadequate Response to Previous Adjunctive Therapy
NCT02012218
Drugs and interventions used in this trial
2 registeredThese interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.
DRUG · Mapped RxNorm record
Brexpiprazole
Normalized identity: brexpiprazoleView linked drug · Find medicine records ·
Find other trials using this name
No matching interventions in this trial.
Study at a glance
Registry-backedBrexpiprazole as Adjunctive Therapy With Major Depressive Disorder and an Inadequate Response to Previous Adjunctive Therapy
Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE3
Read study objectives, eligibility and outcome measures at ClinicalTrials.govAdvertisement
Conditions
Major Depressive Disorder (MDD)unresolved
Interventions
ADTDRUG
BrexpiprazoleDRUG · verified · RxNorm: brexpiprazole
Sponsors & collaborators
Otsuka Pharmaceutical Co., Ltd.collaborator
Mapped research locations
BostonMassachusetts, United States1DallasTexas, United States1BaltimoreMaryland, United States1St LouisMissouri, United States1PortlandOregon, United States1IndianapolisIndiana, United States1OrlandoFlorida, United States1Oklahoma CityOklahoma, United States1MemphisTennessee, United States1SpokaneWashington, United States1RaleighNorth Carolina, United States1DaytonOhio, United States1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT02012218 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.